PIK3CA and prostate cancer: The dual PI3K/mTOR inhibitor X480 was shown to inhibit bone metastasis and tumor-induced osteolysis in vivo as well as inhibits prostate cancer-induced osteoclastogenesis and stimulates osteoblast activity in vitro [100].